scholarly journals Platelet function tests: A 5-year audit of platelet function tests done for bleeding disorders in a tertiary care center of a developing country

2018 ◽  
Vol 61 (3) ◽  
pp. 366
Author(s):  
Sabina Langer ◽  
Jasmita Dass ◽  
Amrita Saraf ◽  
Jyoti Kotwal
2011 ◽  
Vol 15 (3) ◽  
pp. 312-319 ◽  
Author(s):  
Gudithi SWARNALATHA ◽  
Rapur RAM ◽  
Neela PRASAD ◽  
Kaligotla Venkata DAKSHINAMURTY

1992 ◽  
Vol 26 (7-8) ◽  
pp. 926-928 ◽  
Author(s):  
Sarah A. Spinier ◽  
Cheryl A. Elder ◽  
K. Elizabeth Kindwall

OBJECTIVE: To describe propafenone-induced liver injury. DESIGN: Retrospective case report. SETTING: Referred care in a large tertiary care center. Laboratory tests were performed at the auxiliary site and the tertiary care center. PATIENT: A 71-year-old woman with atrial fibrillation developed elevations of greater than two times the upper limit of normal in alkaline phosphatase (ALK), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma glutamyltransferase (GGT) after initiation of propafenone therapy. INTERVENTIONS: Studies included serial measurements of ALK, ALT, AST, and GGT. RESULTS: The patient developed elevations of greater than two times the upper limit of normal in ALK, ALT, and AST, one month after initiating propafenone therapy. The propafenone dose was decreased from 900 to 675 mg/d and, ten days later, the ALK, ALT, and AST were decreased slightly, but still above the upper limit of normal. One month later, serum transaminases had returned to baseline, but propafenone therapy was discontinued because of recurrent atrial fibrillation, persistent elevation in ALK, and elevation in GGT. Two months after discontinuing propafenone, serum aminotransaminase and ALK concentrations had normalized and GGT had decreased and remained only slightly elevated. CONCLUSIONS: The occurrence of liver injury secondary to propafenone therapy is rare. Reported cases appear to be secondary to hepatocellular injury, cholestasis, or a combination of the two. In this case, the pattern demonstrated by elevations in liver enzymes may be classified as acute cholestatic liver injury. Because the reported incidence is 0.1–0.2 percent and there are no known fatalities secondary to propafenone liver injury, routine monitoring of liver function tests in all patients receiving propafenone cannot be recommended at this time. Baseline liver function tests prior to initiating propafenone therapy with follow-up laboratory studies one month later are recommended in patients with known liver dysfunction. If elevations are noted, a reduction in dose may result in lower liver enzyme concentrations, although discontinuation of therapy may be required in some cases.


2011 ◽  
Vol 3 (1) ◽  
pp. 47
Author(s):  
Bassem Jerbi ◽  
Leila Abid ◽  
Souad Mallek ◽  
Dorra Abid ◽  
Souad Mallek ◽  
...  

2017 ◽  
Vol 23 (8) ◽  
pp. S79
Author(s):  
Richard Ferrer ◽  
Rama Nasef ◽  
Bassam Atallah ◽  
Ziad G. Sadik ◽  
Mohammed E. Khalil ◽  
...  

2018 ◽  
Vol 05 (04) ◽  
pp. 302-304
Author(s):  
Ashish Jain ◽  
Mukta Manthan ◽  
Nisha Kumari ◽  
Srijan Singh

2018 ◽  
Vol 20 (suppl_2) ◽  
pp. i130-i130
Author(s):  
Naureen Mushtaq ◽  
Quratulain Riaz ◽  
Cynthia Hawkins ◽  
Vijay Ramaswamy ◽  
Khurram Minhas ◽  
...  

2019 ◽  
Vol 36 (2) ◽  
pp. 330-336 ◽  
Author(s):  
Tanushree Sahoo ◽  
Shano Naseem ◽  
Jasmina Ahluwalia ◽  
R. K. Marwaha ◽  
Amita Trehan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document